LONDON (Alliance News) - Midatech Pharma PLC on Tuesday said it has signed a deal with the Dana-Farber Cancer Institute, an affiliate of Harvard University in the US.
Under the terms of the agreement, Midatech and Dana-Farber will test the pre-clinical effectiveness of Midatech's nanomedicines against Glioblastoma, a type of brain cancer.
No financial terms on the agreement were disclosed.
"This collaboration demonstrates the growing interest in our technology across a range of therapeutic compounds and for specifically targeting certain types of cancer cells," said Jim Philips, Midatech chief executive.
Shares in Midatech were up 1.7% to 305.00 pence Tuesday morning.
By Sam Unsted; samunsted@alliancenews.com; @SamUAtAlliance
Copyright 2015 Alliance News Limited. All Rights Reserved.